George C. Prendergast (born 1961) is an American biomedical scientist. His research has focused on cancer pathobiology and immunology.[1] Since 2004, he has been the president and CEO of Lankenau Institute for Medical Research, a cancer-focused research center in the U.S.[2][3][4] He is also the co-director of the Program in Cancer Cell Biology & Signaling at the Sidney Kimmel Cancer Center, Thomas Jefferson University.[5]
George C. Prendergast | |
|---|---|
 | |
| Born | Philadelphia, Pennsylvania |
| Alma mater | Princeton University Yale University University of Pennsylvania |
| Awards | 1995 Pew Scholar in the Biomedical Sciences |
| Scientific career | |
| Fields | Oncology, Molecular biology, Oncoimmunology |
| Institutions | Lankenau Institute for Medical Research DuPont Pharmaceuticals Company The Wistar Institute Merck Research Laboratories Howard Hughes Medical Institute |
Education
editPrendergast earned his bachelor's degree in biochemistry from the University of Pennsylvania, his master's degree in molecular biophysics and biochemistry from Yale University and his PhD in molecular biology from Princeton University.[6][7][8] He was later an American Cancer Society postdoctoral fellow at the Howard Hughes Medical Institute at New York University Medical Center before working in the Department of Cancer Research at Merck.[9][10]
Career
editIn 1993, Prendergast joined the faculties of The Wistar Institute and the Department of Genetics at the University of Pennsylvania. In 1999, he also became a senior director at the DuPont Pharmaceuticals Company.[11][12]
In 2002, he moved his groups at Wistar and DuPont to the Lankenau Institute for Medical Research (LIMR) and became the president and CEO there in 2004.[13] At LIMR, Prendergast created an organizational model for nonprofit biomedical research termed the acapreneurial™ model, whose stated aim is to balance academic studies with invention, product development and partnered entrepreneurialism.[14][15][16][17]
Prendergast's current research focuses on new uses of IDO1 inhibitory drugs in medicine, investigations of the IDO2 enzyme in cancer and autoimmunity, and therapeutic antibodies that target the disease severity modifier genes Bin1 and RhoB to broadly treat autoimmune disorders and diabetic complications.
His research team pioneered the early discovery and development of experimental drugs that inhibit the tryptophan catabolizing enzyme IDO1 as a new type of oral immunotherapy for cancer,[18] currently under study worldwide.[19]
In 2008, Prendergast was recognized as one of the 250 most influential alumni of Princeton University.[20] From 2010-2017, Prendergast was Editor-in-Chief of Cancer Research, a journal of the American Association for Cancer Research, one of the most cited in the field.[21] In 2018, Prendergast was named The Havens Chair in Biomedical Research by the Lankenau Medical Center Foundation.[22]
Selected publications
edit- Prendergast, GC; Malachowski, WP; DuHadaway, JB; Muller, AJ (2017). "Discovery of IDO1 inhibitors: from bench to bedside". Cancer Research. 77 (24): 6795–6811. doi:10.1158/0008-5472.CAN-17-2285. PMC 6021761. PMID 29247038.
- Prendergast; GC (2011). "Why tumours eat tryptophan". Nature. 478 (7368): 192–4. doi:10.1038/478192a. PMID 21993754.
- Smith, C; Chang, MY; Parker, KH; Beury, DW; DuHadaway, JB; Flick, HE; Boulden, J; Sutanto-Ward, E; Soler, AP; Laury-Kleintop, LD; Mandik-Nayak, L; Metz, R; Ostrand-Rosenberg, S; Prendergast, GC; Muller, AJ (2012). "IDO is a nodal pathogenic driver of lung cancer and metastasis development". Cancer Discovery. 2 (8): 722–35. doi:10.1158/2159-8290.CD-12-0014. PMC 3677576. PMID 22822050.
- Muller, AJ; Prendergast, GC (2005). "Marrying immunotherapy with chemotherapy: why say IDO?". Cancer Research. 65 (18): 8065–8. doi:10.1158/0008-5472.CAN-05-2213. PMID 16166276.
- Muller, AJ; Duhadaway, JB; Donover, PS; Sutanto-Ward, E; Prendergast, GC (2005). "Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy". Nature Medicine. 11 (3): 312–9. doi:10.1038/nm1196. PMID 15711557. S2CID 12338548.
- Sakamuro, D; Elliott, KJ; Wechsler-Reya, R; Prendergast, GC (1996). "BIN1 is a novel MYC-interacting protein with features of a tumour suppressor". Nature Genetics. 14 (1): 69–77. doi:10.1038/ng0996-69. PMID 8782822. S2CID 21484402.
- Ferré-D'Amaré, AR; Prendergast, GC; Ziff, EB; Burley, SK (1993). "Recognition by Max of its cognate DNA through a dimeric b/HLH/Z domain". Nature. 363 (6424): 38–45. Bibcode:1993Natur.363...38F. doi:10.1038/363038a0. PMID 8479534. S2CID 4304430.
- Prendergast, G; Ziff, E (1991). "Methylation-sensitive sequence-specific DNA binding by the c-Myc basic region". Science. 251 (4990): 186–9. Bibcode:1991Sci...251..186P. doi:10.1126/science.1987636. PMID 1987636.
- Prendergast, GC; Lawe, D; Ziff, EB (1991). "Association of Myn, the murine homolog of Max, with c-Myc stimulates methylation-sensitive DNA binding and ras cotransformation". Cell. 65 (3): 395–407. doi:10.1016/0092-8674(91)90457-A. PMID 1840505. S2CID 36903663.
Books
edit- Prendergast GC, editor (2004). Molecular Cancer Therapeutics: Strategies for Drug Discovery and Development. New York: John Wiley & Sons. ISBN 9780471656166. Reviewed in New England Journal of Medicine 352, 422-423 [2005][23]
- Prendergast GC and Jaffee EM, editors (2007). Cancer Immunotherapy: Immune Suppression and Tumor Growth. 1st ed. New York: Academic Press. ISBN 9780123725516. Reviewed in New England Journal of Medicine 358, 1764-1765 [2008] [24]
- Prendergast GC and Jaffee EM, editors (2013). Cancer Immunotherapy: Immune Suppression and Tumor Growth. 2nd ed. New York: Elsevier/Academic Press. ISBN 9780123946331.
References
edit- ^ "George C. Prendergast - Science History". sciencehistory.org. Retrieved 12 November 2008.
- ^ "Lankenau Institute for Medical Research - George C. Prendergast, PhD". Retrieved 29 December 2013.
- ^ "Lankenau Institute for Medical Research: History and Accomplishments".
- ^ "Low-carbohydrate, high-protein diets may reduce both tumor growth rates and cancer risk". sciencedaily.com. Retrieved 15 June 2011.
- ^ Program in Cancer Cell Biology & Signaling, Kimmel Cancer Center, Thomas Jefferson University
- ^ "Resident Faculty of Lankenau Institute for Medical Research: George C. Prendergast, Ph.D."
- ^ "Science History Institute: Oral history interview with George C. Prendergast (2003)".
- ^ "Lankenau Institute for Medical Research: Technology Development and Licensing".
- ^ "Immunochemotherapy: The future of cancer treatment". myabcam.com. Retrieved 18 August 2009.
- ^ "Philadelphia Business Journal: Main Line research institute turns to Jefferson for invention licensing help".
- ^ "Immunochemotherapy: INTERNATIONAL JOURNAL OF ONCOLOGY" (PDF). spandidos-publications.com. Retrieved 31 March 2007.
- ^ "Lankenau Institute for Medical Research President And CEO Invited To Speak At Three Oncology And Biotechnology Conferences This Spring". biospace.com. Retrieved 19 April 2016.
- ^ "Immunochemotherapy: INTERNATIONAL JOURNAL OF ONCOLOGY" (PDF). spandidos-publications.com. Retrieved 31 March 2007.
- ^ "Loop - George C. Prendergast". frontiersin.org. Retrieved 31 December 2001.
- ^ "Philadelphia Business Journal: Main Line research institute turns to Jefferson for invention licensing help".
- ^ "Lankenau Institute for Medical Research President And CEO Invited To Speak At Three Oncology And Biotechnology Conferences This Spring". biospace.com. Retrieved 19 April 2016.
- ^ "Guiding light: Main Line startup taps Lankenau Institute's glow tech to make antibodies". bizjournals.com. Retrieved 30 January 2001.
- ^ Prendergast, George C.; Malachowski, William P.; Duhadaway, James B.; Muller, Alexander J. (15 December 2017). "Discovery of IDO1 Inhibitors: From Bench to Bedside". Cancer Research. 77 (24): 6795–6811. doi:10.1158/0008-5472.CAN-17-2285. PMC 6021761. PMID 29247038.
- ^ "Journal of the National Cancer Institute: Using IDO1 Inhibitors To Combat Cancer".
- ^ "Princeton Alumni Weekly: The List". 21 January 2016.
- ^ "American Association for Cancer Research 2017 Annual Report - Scientific Publishing".
- ^ "Main Line Health: Peter and Louise Havens establish endowed chair for biomedical research at Lankenau". 9 May 2017.
- ^ Takimoto, Chris H. (8 October 2009). "Book Review Molecular Cancer Therapeutics: Strategies for Drug Discovery and Development Edited by George C. Prendergast. 351 pp., illustrated. Hoboken, N.J., John Wiley & Sons, 2004. $89.95. 0-471-43202-4". New England Journal of Medicine. 352 (4): 422–423. doi:10.1056/NEJM200501273520425.
- ^ Weiner, Louis M. (17 April 2008). "Book Review Cancer Immunotherapy: Immune Suppression and Tumor Growth Edited by George C. Prendergast and Elizabeth M. Jaffee. 409 pp., illustrated. San Diego, CA, Elsevier Academic Press, 2007. $99.95. 978-0-12-372551-6". New England Journal of Medicine. 358 (16): 1764–1765. doi:10.1056/NEJMbkrev59011.
External links
edit- George C. Prendergast publications indexed by Google Scholar